Elanco Animal Health Incorporated announced on March 17, 2025, changes to its Board of Directors, which will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders. Paul Herendeen is recommended to succeed Mr. Bilbrey as Chair of the Board's Finance, Strategy and Oversight Committee, bringing deep expertise in finance and the animal health industry.
Concurrently, Elanco signed a research agreement with WEDterinary LLC, a newly formed research engine co-founded by William Doyle. This partnership aims to pursue transformational approaches to healthcare for pets, with an initial focus on targeted gene therapy to treat Chronic Kidney Disease (CKD) in cats and explore emerging spaces to increase healthy lifespan for pets.
Dr. Ellen de Brabander, Executive Vice President of R&D and Regulatory Affairs at Elanco, stated that this partnership increases Elanco's research capacity to refill its innovation pipeline and drive a consistent flow of high-impact innovation. The agreement will be funded within Elanco's research and development operating expenses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.